Romosozumab was found to significantly increase bone mineral density and bone content in the spine and hip in postmenopausal women compared to baseline and also compared to teriparatide and placebo, as presented at the European League Against Rheumatism Annual Congress (EULAR 2014).
Romosozumab was given SC monthly over 12 months to postmenopausal women with lumbar spine, total hip, or femoral neck T-score <-2.0 and >-3.5 at all sites in a Phase 2 international, randomized, placebo-controlled study. Romosozumab had demonstrated increases in both the trabecular and cortical compartments of the spine and hip regions as well as shown differences between romosozumab and teriparatide based on skeletal location.
Treatment with romosozumab and teriparatide achieved similar and significant gains from baseline in trabecular bone mineral density in the lumbar spine (+18.3% vs. +20.1% respectively; P<0.05). At the hip, trabecular bone mineral density gains were significantly larger with romosozumab than teriparatide (10.8% vs. 4.2%, P=0.01).
Lead investigator Professor Harry K. Genant of the University of California an Francisco reported that these results “support the continued clinical investigation of romosozumab as a potential treatment for postmenopausal women with osteoporosis with established bone mineral density deficit who are at increased risk of fracture.”
For more information visit EULAR.org.